Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor; Scott Guerin, PhD

As organizations new to pathways look to develop their processes, it is highly beneficial to examine the foundations used by leaders within each therapeutic area of interest.
For clinical pathways to be most effective, they need to accommodate many external factors impacting patients.
President Donald J Trump’s selection of Scott Gottlieb, MD, to lead the FDA has ushered in a new direction for the government agency, which is likely to alter the availability and use of pharmaceuticals in the United States.